AIMZ Investment Advisors LLC boosted its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 30.3% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 86,090 shares of the company’s stock after purchasing an additional 20,011 shares during the period. Teva Pharmaceutical Industries Limited comprises approximately 2.4% of AIMZ Investment Advisors LLC’s holdings, making the stock its 10th largest position. AIMZ Investment Advisors LLC’s holdings in Teva Pharmaceutical Industries Limited were worth $2,860,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Greylin Investment Mangement Inc. grew its position in Teva Pharmaceutical Industries Limited by 36.9% during the second quarter. Greylin Investment Mangement Inc. now owns 294,495 shares of the company’s stock valued at $9,783,000 after purchasing an additional 79,300 shares in the last quarter. Financial Counselors Inc. grew its position in Teva Pharmaceutical Industries Limited by 5.7% during the second quarter. Financial Counselors Inc. now owns 140,599 shares of the company’s stock valued at $4,671,000 after purchasing an additional 7,571 shares in the last quarter. PGGM Investments grew its position in Teva Pharmaceutical Industries Limited by 12.0% during the second quarter. PGGM Investments now owns 1,528,097 shares of the company’s stock valued at $50,763,000 after purchasing an additional 163,292 shares in the last quarter. GAM Holding AG grew its position in Teva Pharmaceutical Industries Limited by 23.2% during the second quarter. GAM Holding AG now owns 41,900 shares of the company’s stock valued at $1,392,000 after purchasing an additional 7,900 shares in the last quarter. Finally, Chou Associates Management Inc. grew its position in Teva Pharmaceutical Industries Limited by 134.9% during the second quarter. Chou Associates Management Inc. now owns 505,000 shares of the company’s stock valued at $16,839,000 after purchasing an additional 290,000 shares in the last quarter. 56.75% of the stock is currently owned by hedge funds and other institutional investors.

A number of brokerages recently commented on TEVA. Jefferies Group LLC reaffirmed a “hold” rating and set a $26.00 price objective (down from $33.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, August 9th. ValuEngine raised shares of Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. Piper Jaffray Companies set a $23.00 price objective on shares of Teva Pharmaceutical Industries Limited and gave the company a “hold” rating in a research report on Friday, October 6th. Deutsche Bank AG reaffirmed a “buy” rating and set a $28.00 price objective (down from $43.00) on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, August 9th. Finally, Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Teva Pharmaceutical Industries Limited in a research report on Wednesday, October 4th. Five investment analysts have rated the stock with a sell rating, eighteen have issued a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Hold” and an average price target of $27.63.

TRADEMARK VIOLATION WARNING: “Teva Pharmaceutical Industries Limited (TEVA) Position Lifted by AIMZ Investment Advisors LLC” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/11/teva-pharmaceutical-industries-limited-teva-position-lifted-by-aimz-investment-advisors-llc.html.

Teva Pharmaceutical Industries Limited (NYSE TEVA) traded down 0.409% during trading on Wednesday, reaching $15.825. 4,400,371 shares of the company traded hands. The company’s 50-day moving average is $16.83 and its 200 day moving average is $26.44. Teva Pharmaceutical Industries Limited has a 12 month low of $15.22 and a 12 month high of $45.14. The company has a market cap of $16.07 billion, a PE ratio of 3.079 and a beta of 0.57.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.06 by ($0.07). Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The business had revenue of $5.69 billion for the quarter, compared to analyst estimates of $5.72 billion. During the same period in the prior year, the business earned $1.25 EPS. The company’s revenue for the quarter was up 12.9% compared to the same quarter last year. On average, analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.26 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th were issued a dividend of $0.085 per share. This represents a $0.34 annualized dividend and a yield of 2.14%. The ex-dividend date was Friday, August 25th. Teva Pharmaceutical Industries Limited’s dividend payout ratio is -15.36%.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.